scholarly journals Crizotinib‐associated renal cyst development may be associated with prolonged progression‐free survival in patients with ALK ‐positive non‐small‐cell lung cancer: Case report and review of the literature

2021 ◽  
Vol 9 (6) ◽  
Author(s):  
Nathaniel E. Wiest ◽  
Katherine S. Tzou ◽  
Matthew T. Olson ◽  
Steven M. Herchko ◽  
Essa M. Bajalia ◽  
...  
Keyword(s):  
Renal Cyst ◽  
Progression Free Survival ◽  
Small Cell ◽  
Cancer Case ◽  
Lung Cancer Case ◽  
Review Of The Literature ◽  
Small Cell Lung ◽  
Free Survival ◽  
Alk Positive ◽  
Cyst Development

scholarly journals Renal complication of crizotinib: Crizotinib-associated complex renal cyst

2020 ◽  
Vol 21 (1) ◽  
pp. 44-56
Author(s):  
Warissara Jutidamrongphan ◽  
Pimporn Puttawibul
Keyword(s):  
Renal Impairment ◽  
Kinase Inhibitors ◽  
Renal Cyst ◽  
Renal Cysts ◽  
Small Cell ◽  
Small Cell Lung ◽  
Anaplastic Lymphoma ◽  
Renal Complication ◽  
Alk Positive ◽  
Cyst Development

Crizotinib is one of the first generations of tyrosine kinase inhibitors targeting anaplastic lymphoma kinase(ALK) and is recently found to be associated with the development of complex renal cysts with inconclusive explanation up to this time. Hereby, we discuss the hypothesis of Crizotinib-associated complex renal cyst development and coexisting renal impairment after initiation of the treatment in a 75-year-old man with ALK-positive non-small cell lung cancer whose complex renal cysts evolved after initiation and cessation of Crizotinib treatment. The coexistence as renal impairment persisted even after switching from Crizotinib to Ceritinib.

Final progression-free survival results from the J-ALEX study of alectinib versus crizotinib in ALK-positive non-small-cell lung cancer

Lung Cancer ◽  
2020 ◽  
Vol 139 ◽  
pp. 195-199 ◽  
Author(s):  
Kazuhiko Nakagawa ◽  
Toyoaki Hida ◽  
Hiroshi Nokihara ◽  
Masahiro Morise ◽  
Koichi Azuma ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Progression Free Survival ◽  
Small Cell ◽  
Small Cell Lung ◽  
Free Survival ◽  
Alk Positive

scholarly journals Roentgenographically Occult Small-Cell Lung Cancer: Case Report and Review of the Literature

1996 ◽  
Vol 71 (5) ◽  
pp. 481-484 ◽  
Author(s):  
Ikuo Sekine ◽  
Yasutsuna Sasaki ◽  
Masayuki Noguchi ◽  
Ryosuke Ono ◽  
Nagahiro Saijo
Keyword(s):  
Lung Cancer ◽  
Case Report ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Small Cell ◽  
Cancer Case ◽  
Lung Cancer Case ◽  
Review Of The Literature ◽  
Small Cell Lung

Treatment of ALK-Positive Non–Small Cell Lung Cancer

2012 ◽  
Vol 136 (10) ◽  
pp. 1201-1204 ◽  
Author(s):  
Yung-Jue Bang
Keyword(s):  
Lung Cancer ◽  
Phase I ◽  
Phase Ii Study ◽  
Objective Response ◽  
Progression Free Survival ◽  
Small Cell ◽  
Second Line ◽  
Small Cell Lung ◽  
Free Survival ◽  
Alk Positive

Crizotinib (Xalkori), the first inhibitor of both anaplastic lymphoma kinase (ALK) and c-Met receptor kinases, has been approved in the United States, Korea, and other countries for the treatment of ALK-positive non–small cell lung cancer (NSCLC). This approval came within just 4 years of the discovery of rearrangements in the ALK gene in a subset of patients with NSCLC. Oral crizotinib 250 mg twice daily showed excellent efficacy in patients with advanced ALK-positive NSCLC, with objective response rates of 61% and 51% in ongoing phase I and II studies, respectively. Objective response rates of current standard, single-agent, second-line therapies are less than 10%. Median progression-free survival was 10 months (95% confidence interval, 8.2–14.7) in the phase I study expanded cohort and has yet to be reached in the phase II study; progression-free survival with current therapies is less than 3 months. Crizotinib was well tolerated; grade 1/2 gastrointestinal toxicity and visual disturbances were the most common adverse events. Patients in the phase II study reported improvements in fatigue, dyspnea, and cough, based on quality of life assessments. Phase III studies investigating crizotinib for the first- and second-line treatment of advanced ALK-positive NSCLC, versus current standards of care, are ongoing. Crizotinib represents a new standard of care for patients with ALK-positive NSCLC and highlights the importance of the role of the pathologist, as molecular profiling becomes a part of initial workups for newly diagnosed patients with NSCLC. This approach will ensure effective individualized treatment for patients with NSCLC.

scholarly journals Alectinib in Crizotinib-Refractory ALK-Rearranged Non–Small-Cell Lung Cancer: A Phase II Global Study

2016 ◽  
Vol 34 (7) ◽  
pp. 661-668 ◽  
Author(s):  
Sai-Hong Ignatius Ou ◽  
Jin Seok Ahn ◽  
Luigi De Petris ◽  
Ramaswamy Govindan ◽  
James Chih-Hsin Yang ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Progression Free Survival ◽  
Small Cell ◽  
Progression Rate ◽  
Small Cell Lung ◽  
Cns Metastases ◽  
Free Survival ◽  
Alk Positive

Purpose Crizotinib confers improved progression-free survival compared with chemotherapy in anaplastic lymphoma kinase (ALK)-rearranged non–small-cell lung cancer (NSCLC), but progression invariably occurs. We investigated the efficacy and safety of alectinib, a potent and selective ALK inhibitor with excellent CNS penetration, in patients with crizotinib-refractory ALK-positive NSCLC. Patients and Methods Alectinib 600 mg was administered orally twice daily. The primary end point was objective response rate (ORR) by central independent review committee (IRC). Results Of the 138 patients treated, 84 patients (61%) had CNS metastases at baseline, and 122 were response evaluable (RE) by IRC. ORR by IRC was 50% (95% CI, 41% to 59%), and the median duration of response (DOR) was 11.2 months (95% CI, 9.6 months to not reached). In 96 patients (79%) previously treated with chemotherapy, the ORR was 45% (95% CI, 35% to 55%). Median IRC-assessed progression-free survival for all 138 patients was 8.9 months (95% CI, 5.6 to 11.3 months). CNS disease control rate was 83% (95% CI, 74% to 91%), and the median CNS DOR was 10.3 months (95% CI, 7.6 to 11.2 months). CNS ORR in 35 patients with baseline measurable CNS lesions was 57% (95% CI, 39% to 74%). Of the 23 patients with baseline CNS metastases (measurable or nonmeasurable) and no prior radiation, 10 (43%) had a complete CNS response. At 12 months, the cumulative CNS progression rate (24.8%) was lower than the cumulative non-CNS progression rate (33.2%) for all patients. Common adverse events were constipation (33%), fatigue (26%), and peripheral edema (25%); most were grade 1 to 2. Conclusion Alectinib is highly active and well tolerated in patients with advanced, crizotinib-refractory ALK-positive NSCLC, including those with CNS metastases.

Sign in / Sign up

Export Citation Format

Share Document